Deutsche Bank AG Acquires New Position in REGENXBIO Inc. $RGNX

Deutsche Bank AG acquired a new position in shares of REGENXBIO Inc. (NASDAQ:RGNX) during the 2nd quarter, Holdings Channel.com reports. The firm acquired 207,835 shares of the biotechnology company’s stock, valued at approximately $2,490,000.

A number of other hedge funds have also recently added to or reduced their stakes in RGNX. Vanguard Group Inc. grew its position in shares of REGENXBIO by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 3,374,140 shares of the biotechnology company’s stock worth $48,588,000 after acquiring an additional 36,042 shares during the last quarter. State Street Corp lifted its position in REGENXBIO by 15.2% in the 4th quarter. State Street Corp now owns 2,286,736 shares of the biotechnology company’s stock valued at $32,929,000 after purchasing an additional 301,858 shares during the last quarter. AQR Capital Management LLC boosted its stake in REGENXBIO by 5.6% during the 4th quarter. AQR Capital Management LLC now owns 1,361,962 shares of the biotechnology company’s stock valued at $19,612,000 after purchasing an additional 72,307 shares during the period. Integral Health Asset Management LLC boosted its stake in REGENXBIO by 9.1% during the 4th quarter. Integral Health Asset Management LLC now owns 1,200,000 shares of the biotechnology company’s stock valued at $17,280,000 after purchasing an additional 100,000 shares during the period. Finally, Geode Capital Management LLC grew its position in REGENXBIO by 1.7% in the 4th quarter. Geode Capital Management LLC now owns 1,145,206 shares of the biotechnology company’s stock worth $16,495,000 after purchasing an additional 19,658 shares during the last quarter. Institutional investors and hedge funds own 88.08% of the company’s stock.

REGENXBIO Stock Down 0.1%

RGNX opened at $9.37 on Friday. The firm has a market capitalization of $618.51 million, a P/E ratio of -2.47 and a beta of 0.94. The stock has a fifty day moving average of $11.03 and a 200-day moving average of $9.20. REGENXBIO Inc. has a 12-month low of $5.45 and a 12-month high of $16.19.

REGENXBIO (NASDAQ:RGNX) last issued its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.08 by $0.35. The business had revenue of $108.02 million for the quarter, compared to the consensus estimate of $97.63 million. REGENXBIO had a negative return on equity of 220.07% and a negative net margin of 112.58%. On average, analysts expect that REGENXBIO Inc. will post -3.91 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Leerink Partners boosted their price target on REGENXBIO from $17.00 to $18.00 and gave the stock an “outperform” rating in a research report on Monday, June 22nd. HC Wainwright cut their price objective on shares of REGENXBIO from $23.00 to $21.00 and set a “buy” rating on the stock in a research note on Tuesday. Morgan Stanley reaffirmed an “overweight” rating and issued a $18.00 price objective on shares of REGENXBIO in a report on Friday, August 7th. Weiss Ratings reiterated a “sell (e+)” rating on shares of REGENXBIO in a research report on Monday, June 8th. Finally, Barclays cut shares of REGENXBIO from an “overweight” rating to a “hold” rating in a research note on Friday, August 7th. Nine investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $23.27.

Insider Buying and Selling

In other REGENXBIO news, insider Steve Pakola sold 2,161 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $13.64, for a total transaction of $29,476.04. Following the completion of the sale, the insider directly owned 213,009 shares in the company, valued at approximately $2,905,442.76. This trade represents a 1.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In the last three months, insiders sold 58,494 shares of company stock worth $718,232. Company insiders own 14.22% of the company’s stock.

REGENXBIO Company Profile

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.